title: A view on EGFR-targeted therapies from the oncogene-addiction perspective.
abstract: Tumor cell growth and survival can often be impaired by inactivating a single oncogen- a phenomenon that has been called as "oncogene addiction." It is in such scenarios that molecular targeted therapies may succeed. among known oncogenes, the epidermal growth factor receptor (EGFR) has become the target of different cancer therapies. So far, however, the clinical benefit from EGFR-targeted therapies has been rather limited. a critical review of the large amount of clinical data obtained with anti-EGFR agents, carried out from the perspective of the oncogene addiction concept, may help to understand the causes of the unsatisfactory results. In this article we intend to do such an exercise taking as basis for the analysis a few case studies of anti-EGFR agents that are currently in the clinic. There, the "EGFR addiction" phenomenon becomes apparent in high-responder patients. We further discuss how the concept of oncogene addiction needs to be interpreted on the light of emerging experimental evidences and ideas; in particular, that EGFR addiction may reflect the interconnection of several cellular pathways. In this regard we set forth several hypotheses; namely, that requirement of higher glucose uptake by hypoxic tumor cells may reinforce EGFR addiction; and that chronic use of EGFR-targeted antibodies in EGFR-addicted tumors would induce stable disease by reversing the malignant phenotype of cancer stem cells and also by sustaining an anti-tumor T cell response. Finally, we discuss possible reasons for the failure of certain combinatorial therapies involving anti-EGFR agents, arguing that some of these agents might produce either a negative or a positive trans-modulation effect on other oncogenes. It becomes evident that we need operational definitions of EGFR addiction in order to determine which patient populations may benefit from treatment with anti-EGFR drugs, and to improve the design of these therapies.
authors: Center of Molecular Immunology Havana, Cuba ; Biotech Pharmaceuticals Co. Ltd. Beijing, China.
authors: Rolando
authors: R
authors: Perez
authors: Tania
authors: T
authors: Crombet
authors: Joel
authors: J
authors: de Leon
authors: Ernesto
authors: E
authors: Moreno
keywords: EGFR; cetuximab; combination therapy; erlotinib; nimotuzumab; oncogene addiction; targeted therapy
references: Science. 2002 Jul 5;297(5578):63-4
references: 12098689
references: Cancer Res. 2008 May 1;68(9):3077-80; discussion 3080
references: 18451130
references: Breast Cancer Res Treat. 2012 Feb;132(1):153-64
references: 21584665
references: N Engl J Med. 2006 Feb 9;354(6):567-78
references: 16467544
references: Br J Cancer. 2009 Mar 24;100(6):950-8
references: 19293809
references: Nature. 2006 Dec 7;444(7120):756-60
references: 17051156
references: Sci Transl Med. 2011 Sep 7;3(99):99ra86
references: 21900593
references: Head Neck. 2013 Mar;35(3):399-407
references: 22367849
references: N Engl J Med. 2005 Jul 14;353(2):123-32
references: 16014882
references: Cancer Res. 2012 May 15;72(10):2657-71
references: 22419663
references: Cancers (Basel). 2011 Apr 18;3(2):2014-31
references: 24212794
references: Drugs. 2012 Jun 19;72 Suppl 1:28-36
references: 22712795
references: Cancer Biol Ther. 2011 May 1;11(9):793-800
references: 21307659
references: Clin Cancer Res. 2011 Sep 1;17(17):5668-73
references: 21788356
references: Vaccine. 2008 Sep 8;26(38):4918-26
references: 18672015
references: Nat Rev Cancer. 2009 Aug;9(8):550-62
references: 19629070
references: J Neurooncol. 2010 May;97(3):323-37
references: 19855928
references: Clin Cancer Res. 2009 Nov 1;15(21):6639-48
references: 19825949
references: Front Biosci (Landmark Ed). 2011 Jan 01;16:1962-72
references: 21196276
references: Cancer Res. 2001 Jul 1;61(13):5090-101
references: 11431346
references: Exp Cell Res. 2009 Feb 15;315(4):659-70
references: 18992239
references: Cancer Biol Ther. 2010 Mar 1;9(5):343-9
references: 20448462
references: Cancer. 2008 Jun 15;112(12):2710-9
references: 18481809
references: J Clin Invest. 1984 Aug;74(2):647-51
references: 6086719
references: J Clin Oncol. 2007 May 20;25(15):1960-6
references: 17452677
references: N Engl J Med. 2007 Nov 15;357(20):2040-8
references: 18003960
references: Clin Cancer Res. 2011 Apr 15;17(8):2521-7
references: 21248303
references: Future Oncol. 2007 Jun;3(3):277-83
references: 17547522
references: Neurosci Lett. 2010 Feb 12;470(2):115-20
references: 20045038
references: Cancer Res. 2006 Apr 15;66(8):3992-5
references: 16618717
references: Cancer Biol Ther. 2011 Feb 15;11(4):373-82
references: 21150278
references: Nat Med. 2012 Jan 22;18(2):221-3
references: 22270724
references: Med Oncol. 2011 Dec;28 Suppl 1:S197-203
references: 21080109
references: Nature. 1984 May 31-Jun 6;309(5967):418-25
references: 6328312
references: Nat Clin Pract Oncol. 2006 Aug;3(8):448-57
references: 16894390
references: Oncogene. 2013 Jan 3;32(1):27-38
references: 22349823
references: Immunotechnology. 1997 Mar;3(1):71-81
references: 9154469
references: N Engl J Med. 2009 Sep 3;361(10):958-67
references: 19692684
references: J Oral Pathol Med. 2013 Jan;42(1):26-36
references: 22643066
references: Cancer Cell. 2008 May;13(5):385-93
references: 18455122
references: Physiol Rev. 2011 Apr;91(2):733-94
references: 21527736
references: Nat Rev Cancer. 2012 Jul 12;12(8):553-63
references: 22785351
references: Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1815-20
references: 23319610
references: MEDICC Rev. 2009 Jul;11(3):27-33
references: 21483304
references: Lancet. 2011 May 28;377(9780):1846-54
references: 21621716
references: Nat Rev Cancer. 2012 Jan 12;12(2):133-43
references: 22237392
references: Cancer Biol Ther. 2010 Oct 1;10(7):673-81
references: 20647773
references: J Clin Oncol. 2007 Aug 1;25(22):3230-7
references: 17664471
references: Odontology. 2012 Jul;100(2):156-63
references: 21607591
references: Cancer Biol Ther. 2012 Jun;13(8):600-5
references: 22555809
references: J Clin Oncol. 2004 May 1;22(9):1646-54
references: 15117987
references: Nature. 2008 Jul 24;454(7203):436-44
references: 18650914
references: J Clin Oncol. 2012 Oct 1;30(28):3516-24
references: 22949150
references: N Engl J Med. 2009 Apr 2;360(14):1408-17
references: 19339720
references: J Gene Med. 2012 Mar;14(3):151-7
references: 22262303
references: Cancer Res. 2010 Oct 1;70(19):7500-13
references: 20858720
references: PLoS One. 2012;7(2):e32459
references: 22384257
references: Lancet Oncol. 2010 Jun;11(6):521-9
references: 20493771
references: Nature. 2012 Aug 23;488(7412):527-30
references: 22854777
references: Radiother Oncol. 2012 Jun;103(3):373-9
references: 22516777
references: Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17460-5
references: 23033492
references: Lancet Oncol. 2012 Jan;13(1):33-42
references: 22056021
references: J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):191-9
references: 20369376
references: Nature. 1984 Feb 9-15;307(5951):521-7
references: 6320011
references: Int J Cancer. 2006 Nov 1;119(9):2190-9
references: 16841332
references: Cancer Res. 2009 Jul 15;69(14):5851-9
references: 19584289
references: Science. 2007 May 18;316(5827):1039-43
references: 17463250
references: Cancer Cell. 2008 Jun;13(6):472-82
references: 18538731
references: N Engl J Med. 2004 Jul 22;351(4):337-45
references: 15269313
references: PLoS Med. 2005 Mar;2(3):e73
references: 15737014
references: N Engl J Med. 1980 Oct 9;303(15):878-80
references: 7412807
references: Int J Cancer. 2002 Oct 20;101(6):567-75
references: 12237899
references: Stem Cells. 2008 Dec;26(12):3027-36
references: 18802038
references: Clin Cancer Res. 2011 Nov 15;17(22):6958-62
references: 21900389
references: Ann Oncol. 2008 Jun;19(6):1053-9
references: 18304967
references: Surgery. 2012 Sep;152(3):431-40
references: 22770960
references: Oncologist. 2009 Feb;14(2):119-24
references: 19182243
references: J Immunol. 2011 Nov 15;187(10):4954-66
references: 21984704
references: N Engl J Med. 2009 Feb 5;360(6):563-72
references: 19196673
references: Cancer Immunol Immunother. 2007 Nov;56(11):1701-10
references: 17415565
references: Lancet. 2009 May 2;373(9674):1525-31
references: 19410716
references: Clin Colorectal Cancer. 2012 Jun;11(2):101-11
references: 22055112
references: Cancer Cell. 2010 Nov 16;18(5):485-98
references: 21035406